文献速递肝病

二甲双胍在慢性肝病患者中的安全性与药代动力学

The safety and pharmacokinetics of metformin in patients with chronic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-01-21

本研究通过横断面调查(n=34)和前瞻性研究(n=24)评估二甲双胍在慢性肝病患者中的安全性与药代动力学。所有血浆二甲双胍和乳酸浓度均低于推测的安全阈值,药代动力学与无肝病的2型糖尿病患者相似。结论认为慢性肝病患者中二甲双胍药代动力学改变不足以引起安全性担忧。

要点

  • 慢性肝病患者使用二甲双胍后血浆二甲双胍和乳酸浓度均低于安全阈值。
  • 合并2型糖尿病的慢性肝病患者乳酸浓度更高,肝硬化患者乳酸浓度也更高。
  • 慢性肝病患者二甲双胍药代动力学与无肝病的2型糖尿病患者相似。

核心结论

  • 慢性肝病患者中二甲双胍药代动力学改变不足以引起对不安全浓度的担忧。
  • 接受二甲双胍的慢性肝病患者未观察到不安全的血浆乳酸浓度。

研究设计与样本

  • 横断面调查已处方二甲双胍的慢性肝病患者(n=34)。
  • 前瞻性研究给予二甲双胍500 mg速释片每日两次,最长6周(n=24)。
  • 监测血浆二甲双胍和乳酸浓度,并与已发表的无慢性肝病的健康人群和2型糖尿病人群数据比较。

主要发现

  • 所有血浆二甲双胍和乳酸浓度均低于推测的安全阈值(二甲双胍5 mg/L;乳酸5 mmol/L)。
  • 乳酸浓度与平均稳态二甲双胍浓度无关。
  • 慢性肝病患者中,合并2型糖尿病者血浆乳酸浓度比无2型糖尿病者高48%(P < 0.0001)。
  • 合并肝硬化的慢性肝病患者乳酸浓度比无肝硬化者高23%(P = 0.01)。
  • 慢性肝病患者二甲双胍药代动力学与无肝病的2型糖尿病患者相似;表观二甲双胍清除率与肌酐清除率比值较健康人边缘性降低(中位数12.6 vs 14.9,P = 0.03)。

关键数值与推荐

  • 血浆二甲双胍推测安全阈值为5 mg/L。
  • 血浆乳酸推测安全阈值为5 mmol/L。
  • 合并2型糖尿病的慢性肝病患者乳酸浓度较无2型糖尿病者高48%(P < 0.0001)。
  • 合并肝硬化的慢性肝病患者乳酸浓度较无肝硬化者高23%(P = 0.01)。
  • 慢性肝病患者表观二甲双胍清除率与肌酐清除率比值中位数12.6(IQR 9.5-15.9),健康人为14.9(IQR 13.4-16.4),P = 0.03。

临床怎么用

  • 慢性肝病患者使用二甲双胍时,血浆二甲双胍和乳酸浓度通常低于安全阈值。
  • 合并2型糖尿病或肝硬化的慢性肝病患者乳酸浓度相对更高,需关注。
  • 二甲双胍在慢性肝病患者中的药代动力学与无肝病的2型糖尿病患者相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The FDA approved 'label' for metformin lists hepatic insufficiency as a risk for lactic acidosis. Little evidence supports this warning. AIMS: To investigate the safety and pharmacokinetics of metformin in patients with chronic liver disease (CLD). METHODS: Chronic liver disease patients with and without type 2 diabetes mellitus (T2DM) were studied by a cross-sectional survey of patients already prescribed metformin (n = 34), and by a prospective study where metformin (500 mg, immediate release, twice daily) for up to 6 weeks was prescribed (n = 24). Plasma metformin and lactate concentrations were monitored. Individual pharmacokinetics were obtained and compared to previously published values from healthy and T2DM populations without CLD. RESULTS: All plasma metformin and lactate concentrations remained below the putative safety thresholds (metformin, 5 mg/L; lactate, 5 mmol/L). Lactate concentrations were unrelated to average steady-state metformin concentrations. In patients with CLD, T2DM was associated with higher plasma lactate concentrations (48% higher than those without T2DM, P < 0.0001). CLD patients with cirrhosis had 23% higher lactate concentrations than those without cirrhosis (P = 0.01). The pharmacokinetics of metformin in CLD patients were similar to patients with T2DM and no liver disease. The ratio of apparent metformin clearance (CLMet /F) to creatinine clearance was marginally lower in CLD patients compared to healthy subjects (median, interquartile range; 12.6, 9.5-15.9 vs 14.9, 13.4-16.4; P = 0.03). CONCLUSIONS: The pharmacokinetics of metformin are not altered sufficiently in CLD patients to raise concerns regarding unsafe concentrations of metformin. There were no unsafe plasma lactate concentrations observed in CLD patients receiving metformin (ACTRN12619001292167; ACTRN12619001348145).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Smith FC, Stocker SL, Danta M, et al. The safety and pharmacokinetics of metformin in patients with chronic liver disease. Aliment Pharmacol Ther. 2020. PMID: 31960986. doi:10.1111/apt.15635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。